enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by enGene Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $10.1K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$10.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for enGene Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Grossman William | Interim Chief Medical Officer | 5,102 | Sep 24, 2026 | 2 |
| Zoth Lota S. | Director | – | Jun 17, 2026 | 1 |
| Hastings Paul J | Director | – | Jun 17, 2026 | 1 |
| Glickman Richard M | Director | 24,675 | Jun 17, 2026 | 1 |
| Astley-Sparke Philip | Director | – | Jun 17, 2026 | 1 |
| Brunk Gerald A | Director | 238,851Indirect | Jun 17, 2026 | 1 |
| Heffernan Michael Thomas | Director | – | Jun 17, 2026 | 1 |
| Joustra Wouter | Director | – | Jun 17, 2026 | 1 |
| Daws D. Ryan | Chief Financial Officer | – | Feb 3, 2026 | 1 |
| Cooper Ronald Harold Wilfred | CEO & President | 10,000 | Feb 3, 2026 | 1 |
| Buck Jill | Chief Development Officer | – | Feb 3, 2026 | 1 |
| Giguere Lee | Chief Legal Ofc. and Corp Secy | – | Feb 3, 2026 | 1 |
| Cheung Anthony Tzeyew | Chief Scientific Officer | 102,873 | Feb 3, 2026 | 1 |
| Nichols Alexander Julian | Chief Strategy & Ops. Ofc | – | Feb 3, 2026 | 1 |
| Connolly Joan | Chief Technology Officer | – | Feb 3, 2026 | 1 |
| Boyd Matthew Ross | Chief Regulatory Officer | – | Feb 3, 2026 | 1 |
| Sweiti Hussein | Chief Medical Officer | – | Oct 1, 2025 | 1 |
| Pott Amy | Chief Global Comm. Ofc. | – | Jun 16, 2025 | 0 |
| Bos Jasper | Director | – | Jun 16, 2025 | 0 |
| Pruthi Raj Som | Chief Medical Officer | – | Jan 31, 2025 | 0 |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | 10% Owner | 3,032,430 | Nov 1, 2024 | 0 |
| Forbion Growth Management B.V. | 10% Owner | 3,032,430 | Nov 1, 2024 | 0 |
| Fonds De Solidarite Des Travailleurs Du Quebec | 10% Owner | 3,036,153 | Apr 22, 2024 | 0 |
| Lumira Capital Investment Management Inc. | 10% Owner | 238,851Indirect | Feb 21, 2024 | 0 |
| Bryce Richard Paul | Chief Medical Officer | – | Dec 4, 2023 | 0 |
| Forbion Growth Sponsor FEAC I B.V. | 10% Owner | 3,765,932Indirect | Nov 2, 2023 | 0 |
| Hanson Jason David | Chief Executive Officer | – | Nov 2, 2023 | 0 |
| Sullivan James Crowley | Chief Scientific Officer | – | Nov 2, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:40 PM ET | Sep 22 | 2 days | Grossman WilliamInterim Chief Medical Officer | PPurchase | +5.10K | $1.97 | +$10.1K | New position5.10K after | |
| Nov 1, 2024 (view filing)4:15 PM ET | Oct 30 | 2 days | Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% Owner | PPurchase | +561.8K | $8.90 | +$5.00M | +22.7%3.03M after | |
| Oct 18, 2024 (view filing)4:15 PM ET | Dec 27, 2023-Oct 8, 2024 | 296 daysLate | Forbion Growth Opportunities Fund I Cooperatief U.A. and 1 other10% Owner | PPurchase | +470.6K | $6.40 | +$3.01M | +23.5%2.47M after | 13 lots |
| Oct 1, 2024 (view filing) | Sep 27 | 4 days | Cooper Ronald Harold WilfredChief Executive Officer | PPurchase | +10.0K | $5.70 | +$57.0K | New position10.0K after | |
| Apr 22, 2024 (view filing) | Apr 18-22 | 4 days | Fonds De Solidarite Des Travailleurs Du Quebec10% Owner | SSale | −52.5K | $15.00 | −$788.0K | −1.7%3.04M after | 3 lots |